Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. [Review] 

 -  2016 
<br/><br/> Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated benefits for patients with type 2 diabetes including A1C reduction and weight loss with minimal risk of hypoglycemia. This article provides an evidence-based update of safety and tolerability considerations for the clinical use of GLP-1RAs as a class, with a specific detailed review of data from the exenatide clinical trial development program, which has the longest history and availability of safety and tolerability data as the first-approved GLP-1RA. Specific areas covered include comparative risk of hypoglycemia, as well as pancreatic, thyroid, and cardiovascular safety data; clinical guidance regarding current safety and tolerability data is also reviewed. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>1534-4827 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Clinical Trials as Topic<br/>*Glucagon-Like Peptide-1 Receptor/ag [Agonists]<br/>Animals<br/>Antibodies/im [Immunology]<br/>Antibody Formation<br/>Diabetes Mellitus, Type 2/dt [Drug Therapy]<br/>Humans<br/>Hypoglycemia/dt [Drug Therapy]<br/>Hypoglycemic Agents/tu [Therapeutic Use]
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Health Research Institute
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article<br/>Research Support, Non-U.S. Gov't<br/>Review